Efficacy, immunogenicity and safety of a trivalent live human-lamb reassortant rotavirus vaccine (LLR3) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial.

CONCLUSIONS: In Chinese infants, LLR3 provided a substantial protection against RVGE of any-severity, sRVGE and inpatient caused by any serotype, and showed well immunogenicity and safety.
PMID: 32451212 [PubMed - as supplied by publisher]

Source: Vaccine - May 21, 2020 Category: Allergy & Immunology Authors: Xia S, Du J, Su J, Zhou X, Liu Y, Huang L, Yu Q, Xie Z, Gao J, Xu B, Liu Y, Yang H, Guo T Tags: Vaccine Source Type: research